<PAGE> 1
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
------------------------
FORM 10-Q
------------------------
(MARK ONE)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2000
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM ____________ TO ____________ .
COMMISSION FILE NUMBER 0-28402
ARADIGM CORPORATION
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
<TABLE>
<S> <C>
CALIFORNIA 94-3133088
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
</TABLE>
3929 POINT EDEN WAY
HAYWARD, CA 94545
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES INCLUDING ZIP CODE)
(510) 265-9000
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
Indicate the number of shares outstanding of each of the issuer's classes
of common stock, as of the latest practicable date.
<TABLE>
<S> <C>
Common Stock, no par value 18,091,675
(CLASS) (OUTSTANDING AT OCTOBER 31, 2000)
</TABLE>
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
<PAGE> 2
ARADIGM CORPORATION
INDEX
<TABLE>
<CAPTION>
PAGE
NO.
----
<S> <C> <C>
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Statements of Operations (Unaudited)
Three months ended September 30, 2000 and 1999.............. 1
Nine months ended September 30, 2000 and 1999............... 2
Balance Sheets
September 30, 2000 (Unaudited) and December 31, 1999........ 3
Statements of Cash Flows (Unaudited)
Nine months ended September 30, 2000 and 1999............... 4
Notes to Unaudited Financial Statements..................... 5
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations................................... 8
Item 3. Quantitative and Qualitative Disclosure About Market Risk... 11
PART II. OTHER INFORMATION
Item 2. Changes in Securities and Use of Proceeds................... 12
Item 6. Exhibits and Reports on Form 8-K............................ 12
Signature............................................................. 13
Exhibits.............................................................. 14
</TABLE>
i
<PAGE> 3
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
ARADIGM CORPORATION
STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
SEPTEMBER 30,
------------------
2000 1999
------- -------
(UNAUDITED)
<S> <C> <C>
Contract revenues........................................... $ 4,715 $ 5,017
------- -------
Expenses:
Research and development.................................. 11,974 9,155
General and administrative................................ 2,399 2,227
------- -------
Total expenses.................................... 14,373 11,382
------- -------
Loss from operations........................................ (9,658) (6,365)
Interest income............................................. 936 500
Interest expense and other.................................. (413) (183)
------- -------
Net loss.................................................... $(9,135) $(6,048)
======= =======
Basic and diluted net loss per share........................ $ (0.51) $ (0.41)
------- -------
Shares used in computing basic and diluted net loss per
share..................................................... 17,967 14,693
======= =======
</TABLE>
See accompanying notes.
1
<PAGE> 4
ARADIGM CORPORATION
STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<TABLE>
<CAPTION>
NINE MONTHS ENDED
SEPTEMBER 30,
--------------------
2000 1999
-------- --------
(UNAUDITED)
<S> <C> <C>
Contract revenues........................................... $ 15,219 $ 12,154
-------- --------
Expenses:
Research and development.................................. 34,379 24,362
General and administrative................................ 6,925 6,148
-------- --------
Total expenses.................................... 41,304 30,510
-------- --------
Loss from operations........................................ (26,085) (18,356)
Interest income............................................. 2,300 1,494
Interest expense and other.................................. (1,101) (691)
-------- --------
Net loss.................................................... $(24,886) $(17,553)
======== ========
Basic and diluted net loss per share........................ $ (1.47) $ (1.25)
-------- --------
Shares used in computing basic and diluted net loss per
share..................................................... 16,878 14,038
======== ========
</TABLE>
See accompanying notes.
2
<PAGE> 5
ARADIGM CORPORATION
BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARE INFORMATION)
ASSETS
<TABLE>
<CAPTION>
SEPTEMBER 30, DECEMBER 31,
2000 1999
------------- ------------
(UNAUDITED)
<S> <C> <C>
Current assets:
Cash and cash equivalents................................. $ 44,081 $ 9,347
Short-term investments.................................... 9,382 21,912
Receivables............................................... 1,761 3,886
Other current assets...................................... 1,001 1,187
-------- --------
Total current assets.............................. 56,225 36,332
Property and equipment, net................................. 16,671 14,160
Notes receivable from officers.............................. 119 130
Other assets................................................ 417 168
-------- --------
Total assets...................................... $ 73,432 $ 50,790
======== ========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable.......................................... $ 1,919 $ 2,506
Accrued compensation...................................... 3,062 1,275
Deferred revenue.......................................... 4,481 7,361
Other accrued liabilities................................. 2,244 356
Current portion of capital lease obligations.............. 2,416 1,863
-------- --------
Total current liabilities......................... 14,122 13,361
Notes payable............................................... 6,712 3,956
Noncurrent portion of deferred revenue...................... 2,689 3,663
Capital lease obligations, less current portion............. 4,759 5,653
Commitments and contingencies
Shareholders' equity:
Preferred stock, no par value; 5,000,000 shares
authorized; no shares issued or outstanding............ -- --
Common stock, no par value; 40,000,000 shares authorized;
issued and outstanding shares: September 30,
2000 -- 18,002,644; December 31, 1999 -- 14,749,777.... 145,325 99,603
Shareholder notes receivable................................ (138) (163)
Deferred compensation....................................... (257) (379)
Accumulated deficit......................................... (99,780) (74,904)
-------- --------
Total shareholders' equity........................ 45,150 24,157
-------- --------
Total liabilities and shareholders' equity........ $ 73,432 $ 50,790
======== ========
</TABLE>
See accompanying notes.
3
<PAGE> 6
ARADIGM CORPORATION
STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
<TABLE>
<CAPTION>
NINE MONTHS ENDED
SEPTEMBER 30,
--------------------
2000 1999
-------- --------
(UNAUDITED)
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss.................................................. $(24,886) $(17,553)
Adjustments to reconcile net loss to cash used in
operating activities:
Depreciation and amortization.......................... 2,289 1,733
Amortization of deferred compensation.................. 122 122
Changes in operating assets and liabilities:
Receivables.......................................... 2,125 (1,973)
Other current assets................................. 186 (9)
Other assets......................................... -- (89)
Accounts payable..................................... (587) 943
Accrued compensation................................. 1,787 1,353
Other accrued liabilities............................ 1,888 (829)
Deferred revenue..................................... (3,854) (700)
-------- --------
Net cash used in operating activities............. (20,930) (17,002)
-------- --------
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures...................................... (4,800) (2,982)
Purchase of available-for-sale investments................ (10,191) (10,575)
Proceeds from maturities of available-for-sale
investments............................................ 22,731 16,419
-------- --------
Net cash provided by investing activities......... 7,740 2,862
-------- --------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net............... 45,473 25,477
Issuance of notes payable................................. 2,756 2,273
Proceeds from repayments of shareholder notes............. 11 42
Notes receivable from officers............................ 25 7
Proceeds from equipment loans............................. 1,275 3,294
Payments on lease obligations and equipment loans......... (1,616) (1,290)
-------- --------
Net cash provided by financing activities......... 47,924 29,803
-------- --------
Net increase in cash and cash equivalents................... 34,734 15,663
Cash and cash equivalents at beginning of period............ 9,347 10,765
-------- --------
Cash and cash equivalents at end of period.................. $ 44,081 $ 26,428
======== ========
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest.................................... $ 652 $ 674
======== ========
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of warrants for services......................... $ 249 $ 221
======== ========
</TABLE>
See accompanying notes.
4
<PAGE> 7
ARADIGM CORPORATION
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
SEPTEMBER 30, 2000
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization and Basis of Presentation
Aradigm Corporation (the "Company") is a California corporation. Since
inception, Aradigm has been engaged in the development and commercialization of
non-invasive pulmonary drug delivery systems. Through June 1997, the Company was
in the development stage. The Company does not anticipate receiving significant
revenue from the sale of products in the upcoming year. Principal activities to
date have included obtaining financing, recruiting management and technical
personnel, securing operating facilities, conducting research and development,
and expanding commercial production capabilities. These factors indicate that
the Company's ability to continue its research, development and
commercialization activities is dependent upon the ability of management to
obtain additional financing as required.
In the opinion of management, the financial statements reflect all
adjustments, which are of a normal recurring nature, necessary for a fair
presentation. The accompanying financial statements should be read in
conjunction with the financial statements and notes thereto included with the
Company's Annual Report on Form 10-K, as amended. The results of the Company's
operations for the interim periods presented are not necessarily indicative of
operating results for the full fiscal year or any future interim period.
Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the amounts reported in the financial statements and
accompanying notes. Actual results could differ from those estimates.
Cash Equivalents and Investments
The Company considers all highly liquid investments purchased with an
original maturity of three months or less to be cash equivalents. The Company
places its cash and cash equivalents in money market funds, commercial paper and
corporate notes. The Company's short-term investments consist of commercial
paper and corporate notes with maturities ranging from three to twelve months.
The Company classifies its investments as available-for-sale.
Available-for-sale investments are recorded at fair value with unrealized gains
and losses reported in the statement of shareholders' equity. Fair values of
investments are based on quoted market prices, where available. Realized gains
and losses, which have been immaterial to date, are included in interest and
other income and are derived using the specific identification method for
determining the cost of investments sold. Dividend and interest income is
recognized when earned.
Depreciation and Amortization
The Company records property and equipment at cost and calculates
depreciation using the straight-line method over the estimated useful lives of
the respective assets, generally three to seven years. Machinery and equipment
acquired under capital leases is amortized over the useful lives of the assets.
Leasehold improvements are amortized over the shorter of the term of the lease
or useful lives of the improvements.
Revenue Recognition
Contract revenues consist of revenue from collaboration agreements and
feasibility studies. The Company recognizes revenue under the agreements as
reimbursable costs are incurred. Deferred revenue represents the portion of
research payments received that has not been earned. In accordance with contract
terms, milestone payments from collaborative research agreements are considered
reimbursements for costs incurred under the agreements and, accordingly, are
generally recognized as revenue either upon successful completion of the
5
<PAGE> 8
ARADIGM CORPORATION
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS (CONTINUED)
SEPTEMBER 30, 2000
milestone effort when payments are contingent upon completion of the effort or
are based on actual efforts expended over the remaining terms of the agreements
when payments precede the required efforts. Costs of contract revenues
approximate such revenue and are included in research and development expenses.
Refundable development and license fee payments are deferred until the specified
performance criteria are achieved.
Net Loss Per Share
Basic net loss per share has been computed using the weighted average
number of shares of common stock outstanding less the weighted average number of
shares subject to repurchase during the period. No diluted loss per share
information has been presented in the accompanying statements of operations
since potential common shares from stock options and warrants are antidilutive.
2. SHAREHOLDERS' EQUITY
In April 2000, the Company completed a follow-on public offering of common
stock, which raised approximately $42.6 million in net proceeds with the
issuance of 2,875,000 shares of common stock. In March 1999, the Company
completed a private offering, which raised approximately $24.8 million in net
proceeds with the issuance of 2,428,338 shares of common stock.
3. CONTINGENCIES
In June 1998, Eli Lilly and Company ("Lilly") filed a complaint against the
Company in the United States District Court for the Southern District of
Indiana. The complaint made various allegations against the Company, arising
from the Company's decision to enter into an exclusive collaboration with Novo
Nordisk A/S with respect to the development and commercialization of a pulmonary
delivery system for insulin and insulin analogs. The Company has sponsored
various studies of the pulmonary delivery of insulin analogs using materials
supplied by Lilly under a series of agreements dating from January 1996. The
Company and Lilly had also conducted negotiations concerning a long-term supply
agreement under which Lilly would supply bulk insulin to the Company for
commercialization in the Company's AERx Diabetes Management System, and a
separate agreement under which the Company would license certain intellectual
property to Lilly. These negotiations were terminated after the Company
proceeded with its agreement with Novo Nordisk A/S. The complaint seeks a
declaration that Lilly scientists were co-inventors of a patent application
filed by the Company relating to pulmonary delivery of an insulin analog or, in
the alternative, enforcement of an alleged agreement to grant Lilly a
nonexclusive license under such patent application. The complaint also contains
allegations of misappropriation of trade secrets, breach of fiduciary duty,
conversion and unjust enrichment and seeks unspecified damages and injunctive
relief. The Company filed an answer denying all material allegations of the
complaint and a motion for summary judgment directed against all claims in Eli
Lilly's complaint. The Court has issued two written rulings on the Company's
motion substantially limiting the claims against the Company. Specifically, the
Court granted the Company's motion as to Lilly's claim to enforce an alleged
license agreement, for misappropriation of trade secrets, breach of fiduciary
duty, conversion, estoppel and breach of contract (in part) and dismissed those
claims from the case. The Court denied the Company's motion to Lilly's claims
for declaratory relief, unjust enrichment and breach of contract (in part),
based on factual disputes between the parties, and those issues remain to be
resolved. No trial date has been set. Management believes that it has
meritorious defenses against each of Eli Lilly's claims and that this litigation
will not have a material adverse effect on the Company's results of operations,
cash flows or financial position. However, there can be no assurance that the
Company will prevail in this case.
6
<PAGE> 9
ARADIGM CORPORATION
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS (CONTINUED)
SEPTEMBER 30, 2000
4. RECENT ACCOUNTING PRONOUNCEMENTS
In December 1999, the Securities and Exchange Commission ("SEC") issued
Staff Accounting Bulletin No. 101 ("SAB 101"), "Revenue Recognition in Financial
Statements." SAB 101 summarizes some of the SEC's views in applying generally
accepted accounting principles to revenue recognition in financial statements.
In September 2000, the SEC issued Staff Accounting Bulletin No. 101B, which
defers the effective date of SAB 101 until no later than the fourth quarter
2000. The Company is currently evaluating the effect of SAB 101 on its
operations and financial position.
In June 1998, the Financial Accounting Standards Board ("FASB") issued
statement of Financial Accounting Standards No. 133, "Accounting for Derivative
Financial Instruments and for Hedging Activities" ("SFAS 133"), which provides a
comprehensive and consistent standard for the recognition and measurement of
derivatives and hedging activities. In June 1999, FASB issued Financial
Accounting Standards No. 137, which deferred the effective date of SFAS 133 to
fiscal years beginning after June 15, 2000. The adoption of SFAS 133 is not
anticipated to have an impact on the Company's operations and financial position
when adopted as the Company holds no derivative financial instruments and does
not currently engage in hedging activities.
In March 2000, the FASB issued No. 44 ("FIN 44") "Accounting for Certain
Transactions Involving Stock Compensation -- An Interpretation of APB 25." This
Interpretation clarifies (a) the definition of employee for purposes of applying
APB 25, (b) the criteria for determining whether a plan qualifies as a
noncompensatory plan, (c) the accounting consequence of various modifications to
the terms of a previously fixed stock option or award, and (d) the accounting
for an exchange of stock compensation awards in a business combination. This
Interpretation is effective July 1, 2000, but certain conclusions in this
Interpretation cover specific events that occur after December 15, 1998, or
January 12, 2000. To the extent that this Interpretation covers events occurring
during the period after December 15, 1998, or January 12, 2000, but before the
effective date of July 1, 2000, the effects of applying this Interpretation are
recognized on a prospective basis from July 1, 2000. The adoption of FIN 44 does
not have a material impact on the Company's operations and financial position.
7
<PAGE> 10
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
The discussion below contains forward-looking statements that are based on
the beliefs of management, as well as assumptions made by, and information
currently available to management. Future results, performance or achievements
could differ materially from those expressed in, or implied by, any such
forward-looking statements as a result of certain factors, including, but not
limited to, those discussed in this section as well as in the section entitled
"Risk Factors" and elsewhere in the Company's Form 10-K/A filed with the
Securities and Exchange Commission on March 30, 2000.
The business is subject to significant risks including, but not limited to,
the success of research and development efforts, dependence on corporate
partners for marketing and distribution resources, obtaining and enforcing
patents important to the business, clearing the lengthy and expensive regulatory
process and possible competition from other products. Even if the products
appear promising at various stages of development they may not reach the market
or may not be commercially successful for a number of reasons. Such reasons
include, but are not limited to, the possibilities that the potential products
may be found to be ineffective during clinical trials, fail to receive necessary
regulatory approvals, are difficult to manufacture on a large scale, are
uneconomical to market, are precluded from commercialization by proprietary
rights of third parties or may not gain acceptance from health care
professionals and patients. Readers are cautioned not to place undue reliance on
the forward-looking statements contained herein. We undertake no obligation to
publicly release the results of any revision to these forward-looking statements
which may be made to reflect events or circumstances occurring after the date
hereof or to reflect the occurrence of unanticipated events.
OVERVIEW
Since our inception in 1991, we have been engaged in the development of
pulmonary drug delivery systems. As of September 30, 2000, we had an accumulated
deficit of $99.8 million. We have not been profitable since inception and expect
to incur additional operating losses over the next several years as research and
development efforts, preclinical and clinical testing activities and
manufacturing scale-up efforts expand and as we plan and build our late-stage
clinical and early commercial production capabilities. To date, we have not had
any material product sales and do not anticipate receiving significant revenue
from product sales during 2000. The sources of working capital have been equity
financings, equipment lease financings, contract revenues and interest earned on
investments.
We have performed initial feasibility work on a number of compounds and
have been compensated for expenses incurred while performing this work in
several cases pursuant to feasibility study agreements with third parties. Once
feasibility is demonstrated with respect to a potential product, we seek to
enter into development contracts with pharmaceutical corporate partners. We
currently have such agreements pursuant to which we are developing pulmonary
delivery systems with Genentech, Inc., to manage cystic fibrosis with dornase
alfa, the active ingredient in Pulmozyme, with Novo Nordisk A/S, to manage
diabetes using insulin and other blood glucose regulating compounds and with
SmithKline Beecham PLC, to manage acute and breakthrough pain using opioid
analgesics.
Our collaborative agreements with Novo Nordisk and SmithKline Beecham
provide for reimbursement of research and development expenses as well as
additional payments to us as we achieve certain significant milestones. We also
expect to receive royalties from these development partners based on revenues
from partner sales of product and to receive revenue from the manufacturing of
unit dose packets and hand-held devices. We recognize revenues under the terms
of these collaborative agreements as research and development expenses are
incurred, but only to the extent that they are reimbursable.
Our collaborative development agreement with Genentech, entered into May
21, 1999, provides that certain expense reimbursements received from Genentech
under this agreement are subject to repayment if the product does not receive
approval from the Food and Drug Administration ("FDA"). Genentech reimburses
development expenses incurred in the form of loans supported by promissory notes
bearing interest at 2% over the prime rate. Upon receipt of FDA approval, we
will receive a milestone payment that is larger than the loan principal and
accrued interest, allowing the loan to be fully repaid at that time. We will
also receive certain milestone payments at various points of product
development.
8
<PAGE> 11
RESULTS OF OPERATIONS
Three Months Ended September 30, 2000 and 1999
Contract Revenues: Contract revenues for the three months ended September
30, 2000 decreased to $4.7 million from $5.0 million for the same period in
1999. The revenue decrease results primarily from a reduction in partner-funded
project development revenue from SmithKline Beecham offset by an increase in
partner-funded project development revenue from Novo Nordisk and the receipt of
a milestone payment from Genentech. Costs associated with contract revenues are
included in research and development expenses.
Research and Development Expenses: Research and development expenses for
the three months ended September 30, 2000 increased to $12.0 million from $9.2
million for the same period in 1999. The increase results primarily from the
hiring of additional scientific personnel and the expansion of research and
development efforts to support the ongoing programs with Novo Nordisk,
SmithKline Beecham and Genentech.
These expenses represent proprietary research expenses as well as costs
related to contract revenues and include salaries and benefits of scientific and
development personnel, laboratory supplies, consulting services and expenses
associated with the development of manufacturing processes. We expect research
and development spending to increase over the next few years as we continue to
expand our development activities to support current and potential future
collaborations and initiate commercial manufacturing of the AERx systems. The
increase in research and development expenditures cannot be predicted accurately
as it depends in part upon future success in pursuing existing development
collaborations, as well as obtaining new collaborative agreements.
General and Administrative Expenses: General and administrative expenses
for the three months ended September 30, 2000 increased to $2.4 million from
$2.2 million for the same period in 1999. The increase results primarily from
additional personnel and leased facilities to support our expansion of research,
development and manufacturing activities, and increased efforts to develop
collaborative relationships with corporate partners.
Interest Income: Interest income for the three months ended September 30,
2000 increased to $936,000 from $500,000 for the same period in 1999. The
increase is due to the Company maintaining larger cash and investment balances.
The higher cash and investment balances in the current period are due to the
Company receiving net proceeds from a follow-on public offering of common stock
for approximately $42.6 million in April 2000. The cash and investment balances
for the same prior year period are due to the Company receiving net proceeds
from a private offering of common stock for approximately $24.8 million in March
1999.
Interest Expense and Other: Interest expense and other for the three months
ended September 30, 2000 increased to $413,000 from $183,000 for the same period
in 1999. The increase is primarily due to higher interest expense on increasing
loan balances that result from reimbursement of development expenses from
Genentech and interest expense on capital lease and equipment loan balances.
Nine Months Ended September 30, 2000 and 1999
Contract Revenues: Contract revenues for the nine months ended September
30, 2000 increased to $15.2 million from $12.2 million for the same period in
1999. The revenue increase resulted primarily from the expansion of
partner-funded project development revenue from Novo Nordisk and the receipt of
a milestone payment from Genentech offset by a reduction in partner-funded
project development revenue from SmithKline Beecham. Costs associated with
contract revenues are included in research and development expenses.
Research and Development Expenses: Research and development expenses for
the nine months ended September 30, 2000 increased to $34.4 million from $24.4
million for the same period in 1999. The increase is primarily attributable to
the hiring of additional scientific personnel and the expansion of research and
9
<PAGE> 12
development efforts to support the ongoing programs with Novo Nordisk,
SmithKline Beecham and Genentech.
General and Administrative Expenses: General and administrative expenses
for the nine months ended September 30, 2000 increased to $6.9 million from $6.1
million for the same period in 1999. The increase results primarily from
additional personnel and leased facilities to support our expansion of research,
development and manufacturing activities, and increased efforts to develop
collaborative relationships with corporate partners.
Interest Income: Interest income for the nine months ended September 30,
2000 increased to $2.3 million from $1.5 million for the same period in 1999.
The increase is due to the Company maintaining larger cash and investment
balances. The higher cash and investment balances in the current period are due
to the Company receiving net proceeds from a follow-on public offering of common
stock for approximately $42.6 million in April 2000. The cash and investment
balances in the same prior year period are due to the Company receiving net
proceeds from a private offering of common stock for approximately $24.8 million
in March 1999.
Interest Expense and Other: Interest expense and other for the nine months
ended September 30, 2000 increased to $1.1 million from $700,000 for the same
period in 1999. The increase is primarily due to higher interest expense on
increasing loan balances that result from reimbursement of development expenses
from Genentech and interest expense on capital lease and equipment loan
balances.
LIQUIDITY AND CAPITAL RESOURCES
The business has financed its operations since inception primarily through
private placements and public offerings of capital stock, proceeds from
equipment lease financing, contract revenues and interest earned on investments.
As of September 30, 2000, we have received approximately $145.3 million in net
proceeds from sales of capital stock. During the quarter, the company
established three new and negotiated an increase in one existing equipment lines
of credit, which total approximately $15.7 million. None of these new equipment
lines of credit had been utilized by September 30, 2000. As of September 30,
2000, we had cash, cash equivalents and short-term investments of approximately
$53.5 million. In April 2000, we completed a follow-on public offering of common
stock, which raised approximately $42.6 million in net proceeds with the
issuance of 2,875,000 shares of common stock.
During November 2000, the Company announced that it entered into a
definitive agreement with Acqua Wellington North American Equities Fund Ltd. for
an equity financing agreement covering the sale of up to $50 million of the
Company's common stock over the next 20 months. The total number of shares may
be sold over time with the Company controlling the amount and timing of stock
sales.
Net cash used in operating activities for the nine months ended September
30, 2000 increased to $20.9 million from $17.0 million for the same period in
1999. The increase in net cash used resulted from decreases in receivables,
other current assets, accounts payable and deferred revenue combined with
increases in accrued compensation and other accrued liabilities offset by an
increase in the net loss.
Net cash provided by investing activities for the nine months ended
September 30, 2000 increased to $7.7 million from $2.9 million for the same
period in 1999. The increase results primarily from increased maturities of
available-for-sale investments partially offset by increased purchases of
investments and capital expenditures.
Net cash provided by financing activities for the nine months ended
September 30, 2000 increased to $47.9 million from $29.8 million for the same
period in 1999. The increase primarily reflects receipt of proceeds from the
completion of a follow-on public offering of common stock in April 2000 which
raised approximately $42.6 million in net proceeds, exercise of incentive stock
options by Company employees and the issuance of notes payable supporting loans
received under a collaborative development agreement with Genentech reduced by
net payments from the use of equipment lines of credit.
10
<PAGE> 13
The development of our technology and proposed products will require a
commitment of substantial funds to conduct the costly and time-consuming
research, preclinical studies and clinical trial activities necessary to develop
and refine the technology and proposed products and bring such products to
market. Future capital requirements will depend on many factors, including
continued progress and results from research and development for the technology
and drug delivery systems, the ability to establish and maintain favorable
collaborative arrangements with others, progress with preclinical studies and
clinical trials and the results thereof, the time and costs involved in
obtaining regulatory approvals, the cost of development and the rate of scale-up
for the required production technologies, the costs involved in preparing,
filing, prosecuting, maintaining and enforcing patent claims and the need to
acquire licenses or other rights to new technology.
We expect that our cash requirements will increase in future periods and
that the business will need to raise additional capital before it becomes
profitable. Based on projected cash requirements, we believe that existing
capital resources and committed funding from the collaborative partners,
together with the proceeds from the April 2000 offering, projected interest
income and the new equity financing agreement covering the sale of additional
common stock should enable the business to maintain current and planned
operations, including anticipated capital spending requirements of approximately
$50 million, through the end of 2001. However, there can be no assurance the
business will not need to raise substantial additional capital to fund the
operations and capital spending during this period. We may seek additional
funding through collaborations or through public or private equity or debt
financing. There cannot be any assurance that additional financing can be
obtained on acceptable terms, or at all. If additional funds are raised by
issuing equity securities, dilution to shareholders may result. If adequate
funds are not available, the business may be required to delay, reduce the scope
of, or eliminate one or more of the research and development programs, or obtain
funds through arrangements with collaborative partners or other sources that may
require the business to relinquish rights to certain technologies or products
that would otherwise not be relinquished.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Market Risk Disclosures
In the normal course of business, our financial position is routinely
subject to a variety of risks, including market risk associated with interest
rate movement. We regularly assess these risks and have established policies and
business practices to protect against these and other exposures. As a result, we
do not anticipate material potential losses in these areas.
As of September 30, 2000, we had cash and cash equivalents and short-term
investments of $53.5 million consisting of cash and highly liquid short-term
investments. Our short-term investments will decline by an immaterial amount if
market interest rates increase, and therefore, our exposure to interest rate
changes has been immaterial. Declines of interest rates over time will, however,
reduce our interest income from our short-term investments. Our outstanding
capital lease obligations are all at fixed interest rates and, therefore, have
minimal exposure to changes in interest rates.
11
<PAGE> 14
PART II. OTHER INFORMATION
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
Changes in Securities
Pursuant to a Lease between the Company and Hayward Point Eden I Limited
Partnership ("Hayward"), dated July 1, 2000 (the "Lease"), the Company agreed to
issue a warrant to purchase 25,000 shares of Common Stock of the Company (the
"Warrant") to Hayward in connection with the execution of a Lease. The Warrant
will have an exercise price of $21.72 per share and will be exercisable for a
period of seven years from the Initial Grant Date (as defined in the Lease). The
Warrant will be issued in reliance on Section 4(2) of the Securities Act of
1933, as amended.
ITEM 6. EXHIBITS
(a) Exhibits
<TABLE>
<S> <C>
10.26 Lease agreement for property located at 2704 West Winton
Avenue, Hayward, California, dated September 11, 2000,
between the Company and Winton Industrial Center, Inc.
10.27 Lease agreement for property located at 3930 Point Eden Way,
Hayward, California, dated July 1, 2000, between the Company
and Hayward Point Eden I Limited Partnership.
27.1.1 Financial Data Schedule
</TABLE>
(b) Reports on Form 8-K
The Company did not file any reports on Form 8-K during the quarter ended
September 30, 2000.
12
<PAGE> 15
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Dated: November 13, 2000
ARADIGM CORPORATION
(Registrant)
/s/ RICHARD P. THOMPSON
--------------------------------------
Richard P. Thompson
President and Chief Executive Officer
/s/ NORMAN HALLEEN
--------------------------------------
Norman Halleen
Vice President, Finance and
Administration
and Chief Financial Officer
13
<PAGE> 16
INDEX TO EXHIBITS
<TABLE>
<CAPTION>
EXHIBIT
NUMBER DESCRIPTION
------- -----------
<C> <S>
10.26 Lease agreement for property located at 2704 West Winton
Avenue, Hayward, California, dated September 11, 2000,
between the Company and Winton Industrial Center, Inc.
10.27 Lease agreement for property located at 3930 Point Eden Way,
Hayward, California, dated July 1, 2000, between the Company
and Hayward Point Eden I Limited Partnership.
27.1 Financial Data Schedule
</TABLE>
14
